Salute e Benessere

GBI Secures Commercial Manufacturing Contract, Solidifying Leadership in…

As the demand for radiopharmaceuticals continues to rise, GBI is positioned to meet the needs of our clients with significantly increased investments in our state-of-the-art development and manufacturing capabilities. As the demand for radiopharmaceuticals continues to rise, GBI is positioned to meet the needs of our clients with significantly increased investments in our state-of-the-art development and manufacturing capabilities. "We are happy to see more clients entrusting us with…
PR Newswire
09/01/2024

SkylineDx Announces Grant of European Patent and Advances in Melanoma Diagnosis…

Dharminder Chahal, CEO of SkylineDx, expressed his pride in this achievement, stating, "Obtaining the European Patent is a testament to SkylineDx's commitment to advancing the field of melanoma diagnosis and treatment. It is a recognition of the important work that our team is doing in collaboration with Mayo Clinic. Our innovative methods for classifying and treating primary cutaneous melanoma represent a significant leap forward in providing personalized care for patients. We are proud to…
PR Newswire
09/01/2024

Unchained Labs rolls out the red carpet for the king of LNP…

Enter Stunner, the first instrument to pull all this LNP data together from one tiny 2 µL sample. Stunner uses rotating angle dynamic light scattering to measure LNPs from a bunch of angles to give researchers accurate sizing, particle concentration and a read on aggregation. In the same 2-minute experiment it uses UV/Vis with precision of 1% and accuracy of 2% to quantify the total payload present. Then it combines payload and particle concentration to report out on loading. For the first time…
PR Newswire
09/01/2024

Domingo Zapata And Sita Abellán's NFT Series Is Launching 2024

The Panda NFTs will be 3D and a select 50 will be individually styled by Sita who has designed pieces for Fendi and Nike, styled celebrities, and designs her own Rihanna approved Lilith jewelry line. The Panda NFTs will be 3D and a select 50 will be individually styled by Sita who has designed pieces for Fendi and Nike, styled celebrities, and designs her own Rihanna approved Lilith jewelry line. Sita invited J Balvin and Anitta to participate on Launch day, styling their own pandas...
PR Newswire
09/01/2024

Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors

"I am honored to join the Oncolytics board at this exciting time for the organization as it advances pelareorep toward registrational studies," said Ms. Andrews. "Promising recent results from the BRACELET-1 and GOBLET studies suggest that pelareorep has the potential to make an important contribution to cancer care, and I look forward to working with my fellow board members in addition to Dr. Coffey and the Executive Team to execute Oncolytics' clinical and corporate development…
PR Newswire
09/01/2024

TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application…

Media Release COPENHAGEN, Denmark; January 9, 2024 TIVDAK sBLA accepted for priority review, FDA action date is May 9, 2024Submission based on positive results from global phase 3 innovaTV 301 trial demonstrating overall survival benefit of tisotumab vedotin-tftv over chemotherapy Genmab A/S(Nasdaq: GMAB) andPfizer, Inc.(NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) seeking to...
Nasdaq GlobeNewswire
09/01/2024

BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan…

Plans to have ten or more potentially registrational trials by the end of 2024 Preparing to be commercial-ready by the end of 2025 Ended 2023 with approximately €17.5 billion (unaudited) in cash, cash equivalents and security investments Expects full year 2024 revenues of approximately €3 billionPresentation and webcast at the 42 ndAnnual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 6:00 p.m. CET/ 12:00 p.m. ET Mainz, Germany, January 9, 2024 (GLOBE...
Nasdaq GlobeNewswire
09/01/2024

British Luxury Phone Brand XOR Makes Its Debut in the Chinese Market

Hutch Hutchison, Head of Design at XOR, states, "We are delighted to introduce XOR to the Chinese market. China has a vibrant luxury landscape, and we believe our unique products will cater to the local customer's pursuit of exceptional quality, exclusive design, and privacy protection." Hutch Hutchison, Head of Design at XOR, states, "We are delighted to introduce XOR to the Chinese market.Chinahas a vibrant luxury landscape, and we believe our unique products will cater to the…
PR Newswire
09/01/2024

Novo Nordisk Foundation partners with CARB-X to fight drug-resistant infections

Antimicrobial resistance (AMR) threatens to unravel societies and the global economic system by increasing the risks of performing routine medical procedures such as caesarean sections, hip replacements and chemotherapy, impairing our food chain, and diminishing productivity. The most comprehensive assessment of the burden of AMR to date found that drug-resistant bacterial infections alone caused an estimated 3,500 deaths every day in 2019, a number on the rise and already higher than both…
PR Newswire
09/01/2024

Acousia Therapeutics attracts new investor on its path to make hearing loss a…

Tim Boelke, CEO of Acousia Therapeutics, said, "Adding Esperante Ventures with their existing position in inner ear therapeutics to our investor syndicate – amidst a challenging macro-economic environment and despite recent drawbacks in competing hearing loss drug development programs – is a testament to the confidence in our unique and proprietary Kv7.4 activator approach. Our lead candidate ACOU085, currently in Clinical Phase 2, aims to set a new standard for treating acute and subacute…
PR Newswire
09/01/2024

Leqembi® approved for the treatment of Alzheimer's disease in China

Leqembi's approval in China is based on the large global Phase 3 Clarity AD study. In the Clarity AD study, Leqembi met its primary endpoint and all key secondary endpoints with statistically significant results. In November 2022, the results of the Clarity AD study were presented at the 2022 Clinical Trials on Alzheimer's Disease (CTAD) conference, and simultaneously published in the New England Journal of Medicine, a peer-reviewed medical journal. Leqembi's approval inChinais based on the...
PR Newswire
09/01/2024

Global Pharmacy Automation Systems Market is expected to grow at a CAGR of…

The global pharmacy automation systems market has witnessed remarkable growth in recent years, driven by the increasing demand for efficient and accurate medication management solutions. With healthcare systems worldwide facing challenges related to rising prescription volumes, medication errors, and the need for improved patient care, pharmacy automation systems have emerged as essential tools for streamlining processes and enhancing overall operational efficiency. The global pharmacy...
PR Newswire
09/01/2024

Zedsen partners with Imperial College Healthcare NHS Trust to clinically…

The clinical research study is titled "An Investigation into Dielectric Assessment of Permittivity of Cancer in Human Using a Novel Electrical Capacitance Tomography Scanner," or "DiCECT" and comprises 90 participants at Charing Cross Hospital. The study is split into 2 parts, with Part A recruiting 20 participants to assess whether the Z-Scanner results can be repeated and reproduced by different users and devices. Part B will recruit 70 participants to assess whether the…
PR Newswire
09/01/2024

EQT introduces the EQT Healthcare Growth Strategy, a dedicated healthcare buyout…

Long-term trends – such as growing, aging, and less healthy populations, significant unmet medical needs, and rising healthcare costs – are leading to a greater need for better, more efficient, and accessible healthcare. At the same time, scientific breakthroughs and advancements in technology and data are accelerating healthcare innovation. This is increasing the opportunity to invest in innovative and differentiated products and services that seek to deliver positive outcomes across the value…
PR Newswire
09/01/2024

Aker ASA - Contemplating NOK Bond Issue

This information is subject to the disclosure requirements pursuant to section 5 -12 the Norwegian Securities Trading Act. This information is subject to the disclosure requirements pursuant to section 5 -12 the Norwegian Securities Trading Act. View original content: https://www.prnewswire.co.uk/news-releases/aker-asa---contemplating-nok-bond-issue-302029375.html
PR Newswire
09/01/2024

Welcome to SciBase Capital Markets Day 2024

During SciBase's Capital Markets Day, Pia Renaudin, who assumed the role of CEO in October 2023, will provide insights into SciBase's future trajectory, and unveil an updated strategic outlook, and long-term strategic goals. The presentations will underscore the company's focus on the USA and shed light on SciBase's ongoing expansion into promising new markets. During SciBase's Capital Markets Day,Pia Renaudin, who assumed the role of CEO inOctober 2023, will provide insights into...
PR Newswire
09/01/2024

Press Release: Brian Foard appointed Head of Specialty Care Global Business…

Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive CommitteeParis, January 9, 2024. Brian Foard, a healthcare industry veteran and Sanofi leader in the U.S., has been named Head of the company's Specialty Care Global Business Unit (GBU). With this appointment, which is effective immediately, Brian becomes a member of Sanofi's Executive Committee.Brian has been interim Head of the GBU since September 2023 while also serving as Head of...
Nasdaq GlobeNewswire
09/01/2024

Chiesi Group and Oak Hill Bio announce License and Development Agreement to…

"Targeting a challenging complication of prematurity with an innovative solution is an important step given the potential benefits it may bring to the babies born extremely prematurely" commented Giuseppe Accogli, CEO of Chiesi Group. "This potentially transformative therapy may provide a breakthrough solution for bronchopulmonary dysplasia, one of the diseases with the highest unmet medical needs in the field of neonatology." " Targeting a challenging complication of…
PR Newswire
09/01/2024

Addex to Present at the Swiss Equities Baader Conference

Geneva, Switzerland, January 9, 2024 - Addex Therapeutics(SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Dr Robert Lütjens, Head of Discovery - Biology, will present at theSwiss Equities Baader Conferencebeing held in Bad Ragaz, Switzerland, January 10-12, 2024.In his presentation, Dr Lütjens will provide a corporate update and discuss recent advances from Addex's CNS pipeline...
Nasdaq GlobeNewswire
09/01/2024

EssilorLuxottica showcases its smart and hearing aided eyewear innovation with…

EssilorLuxottica showcases its smart and hearing aided eyewear innovation with first appearance at CES 2024 in Las VegasThe Company's booth will showcase Nuance Audio, first-of-its-kind glasses with advanced hearing solution, as well as Ray-Ban Meta smart glasses and other innovative solutions in the world of opticsCharenton-le-Pont, France (January 9, 2024 – 7:00 am CET)– For the first time, EssilorLuxottica will exhibit at the Consumer Electronics Show (CES) in Las Vegas January...
Nasdaq GlobeNewswire
09/01/2024

Hematopoietic Stem Cell Transplantation Market to Grow Rapidly During the Study…

Key Takeaways from the Hematopoietic Stem Cell Transplantation Market Report Key Takeaways from the Hematopoietic Stem Cell Transplantation Market Report Discover which therapies are expected to grab the major HSCT market share @Hematopoietic Stem Cell Transplantation Market Report Hematopoietic Stem Cell Transplantation Overview Hematopoietic stem cell transplantation (HSCT) is a medical procedure wherein healthy hematopoietic stem cells (HSC) are introduced into...
PR Newswire
08/01/2024

BIOVAXYS ANNOUNCES PLANNED PRIVATE PLACEMENT AND DEBT SETTLEMENT

All securities issued pursuant to the Private Placement are subject to a statutory hold period of four months and one day from the date of issuance. The Company intends to use the net proceeds of the Private Placement for working capital purposes and for the potential acquisition described in a previous press release dated December 22nd, 2023. All securities issued pursuant to the Private Placement are subject to a statutory hold period of four months and one day from the date of issuance...
PR Newswire
08/01/2024

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) Listing market: Euronext GrowthISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting rights 12/31/202371,751,20177,686,718 For further information on Cellectis, please contact: Media contact: Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, media@cellectis.com Investor Relations contacts: ...
Nasdaq GlobeNewswire
08/01/2024

Tecan reports underlying sales growth of 6.3% for full year 2023

Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports underlying sales growth of 6.3% for full year 2023Männedorf, Switzerland, January 9, 2024 –In a trading statement, the Tecan Group (SIX Swiss Exchange: TECN) today published unaudited preliminary sales results for fiscal year 2023, with an underlying sales growth of 6.3% in local currencies. Tecan CEO Dr. Achim von Leoprechting commented: «Tecan's solid underlying sales growth...
Nasdaq GlobeNewswire
08/01/2024
Altri  Comunicati